53878-12-9

Basic information

• Product Name: 7-(bromomethyl)-2H-chromen-2-one
• CAS NO: 53878-12-9
• Molecular Formula: C₁₀H₇BrO₂
• Molecular Weight: 239.0654
• Mol File: 53878-12-9.mol
• Article Data: 14

Chemical Properties

• Boiling Point: 368.2°C at 760 mmHg
• Flash Point: 176.5°C
• Density: 1.63g/cm³
• Vapor Pressure: 1.3E-05mmHg at 25°C
• Refractive Index: 1.633
• CAS DataBase Reference: 7-(bromomethyl)-2H-chromen-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: 7-(bromomethyl)-2H-chromen-2-one(53878-12-9)
• EPA Substance Registry System: 7-(bromomethyl)-2H-chromen-2-one(53878-12-9)

Safety Data

• Hazardous Substances Data: 53878-12-9(Hazardous Substances Data)

Upstream product

• 2445-83-2 7-methylcoumarin 
• 94-36-0 dibenzoyl peroxide 

Relevant articles and documents

Ultrasound assisted synthesis of coumarin thioglycopyranoside derivatives

Themethyl coumarins reacted with N-bromo-succinimide gave compounds (a～c) which on further reacted with various peracetyl sulfhydryl glycose (1～3) afforded a series of novel coumarin thioglycopyranoside compounds (1a～1c, 2a～2c, 3a～3c). And when used ultra

3-(2-Aminocarbonylphenyl)propanoic acid analogs as potent and selective EP3 receptor antagonists. Part 2: Optimization of the side chains to improve in vitro and in vivo potencies

A series of 3-[2-{[(3-methyl-1-phenylbutyl)amino]carbonyl}-4-(phenoxymethyl)phenyl]propanoic acid analogs were synthesized and evaluated for their in vitro potency. In most cases, introduction of one or two substituents into the two phenyl moieties resulted in the tendency of an increase or retention of in vitro activities. Several compounds, which showed excellent subtype selectivity, were evaluated for their inhibitory effect against PGE2-induced uterine contraction in pregnant rats, which is thought to be mediated by the EP3 receptor subtype. The structure-activity relationships (SARs) are also discussed.

CARBOXAMIDE COMPOUNDS AND THEIR USE AS ANTAGONISTS OF THE CHEMOKINE CCR2 RECEPTOR

Chemokine receptor antagonists, in particular, compounds of Formula (I) that act as antagonists of the chemokine CCR2 receptor, including pharmaceutical compositions and uses thereof to treat or prevent diseases associated with monocyte accumulation, lymphocyte accumulation or leukocyte accumulation are described; wherein (B/A) is an optionally substituted fused aromatic or partially aromatic bicyclic ring containing at least one nitrogen atom.